Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
17-AAG in Relapsed/Refractory Lymphomas
NCT00117988Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Feb 2005
- Primary completion
- Apr 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tanespimycin in anaplastic large cell lymphoma (ALCL), mantle cell lymphoma (MCL) and Hodgkin lymphoma (HL), sponsored by National Cancer Institute. Primary endpoints: Complete and Partial Response Rates and Time to Treatment Failure. Started Feb 2005; status: completed.
02
Drugs
tanespimycin
03
Conditions
anaplastic large cell lymphoma (ALCL)mantle cell lymphoma (MCL)Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT00117988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00117988.